Wall Street analysts expect Merit Medical (MMSI) to post quarterly earnings of $0.75 per share in its upcoming report, which indicates a year-over-year decline of 2.6%. Revenues are expected to be $352.33 million, up 8.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Merit Medical metrics that are commonly monitored and projected by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Cardiovascular- Peripheral Intervention' reaching $141.95 million. The estimate points to a change of +5.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Cardiovascular- Cardiac Intervention' will likely reach $98.79 million. The estimate suggests a change of +8.9% year over year.
Based on the collective assessment of analysts, 'Revenue- Endoscopy' should arrive at $17.89 million. The estimate suggests a change of +76.5% year over year.
Analysts expect 'Revenue- Cardiovascular- OEM' to come in at $43.84 million. The estimate points to a change of +11.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Cardiovascular' will reach $334.45 million. The estimate indicates a year-over-year change of +6.7%.
The consensus among analysts is that 'Revenue- Cardiovascular- Custom Procedural Solutions' will reach $49.74 million. The estimate points to a change of +1.9% from the year-ago quarter.
The consensus estimate for 'Geographic Sales- United States' stands at $208.66 million. The estimate suggests a change of +12.1% year over year.
The average prediction of analysts places 'Geographic Sales- International' at $143.33 million. The estimate suggests a change of +4.3% year over year.
View all Key Company Metrics for Merit Medical here>>>
Over the past month, shares of Merit Medical have returned -10.6% versus the Zacks S&P 500 composite's -5.6% change. Currently, MMSI carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
